Neurocrine Biosciences, Inc.

Cylene Pharmaceuticals, Inc.

Sb Pharmco Puerto Rico Inc.

Collin Regan

Zhiqiang Guo

Michael Schwaebe

Jeffrey Paul Whitten

Jaimie Karyn Rueter

Fabrice Pierre

Charles Q Huang

Yun-Fei Zhu

Yongsheng Chen

Michael E Jung

Chen Chen

Fabrizio Micheli

Romano Di Fabio

Johnny Yasuo Nagasawa

Neil Ashweek

Fabio C Tucci

Dongpei Wu

George Yiannikouros

Yves St-Denis

Peter C Chua

Juan Pablo Cueva-Garcia

The present disclosure relates to compounds of Formula (I) that modulate the activity of G-protein coupled receptor 52 (GPR52), pharmaceutically acceptable salts of compounds of Formula (I), and pharmaceutical compositions thereof. Compounds, pharmaceutical salts of compounds, and pharmaceutical compositions of the present disclosure are directed to methods useful in the treatment or prophylaxis of a neurological disease or disorder and conditions related thereto.

GPR52 modulators and methods of use

The present invention provides quinolone analogs which may inhibit cell proliferation and/or induce cell apoptosis. The present invention also provides methods of preparing quinolone analogs, and methods of using the same.

Quinolone analogs

The present invention relates to methods of preparing compounds having formula (1), (2), (5), and ((6A)-(6D)) 

Methods for converting quinolone esters into quinolone amides

GnRH receptor antagonists are disclosed that have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure: wherein R, R, R, R, R, R, R, R, Rand X are as defined herein, including stereoisomers, prodrugs and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Gonadotropin-releasing hormone receptor antagonists and methods relating thereto

The present invention relates to tricyclic pyridines compounds of formula (I) including stereoisomers, prodrugs and pharmaceutically acceptable salts or solvates thereof: 

Phenyl-5,6,6A,7,8,9-hexahydro-4H-1,4,9-triaza-phenalene derivatives as CRF antagonists

Growing community of inventors

San Diego, CA, United States of America

Collin Regan